Drug Trial Radar · NCT05711394
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
May 1, 2023
Primary completion
Mar 2028
Study completion May 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide. Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
Conditions
- Episodic Migraine
Interventions
AtogepantDrug
Oral Tablet
Placebo-Matching AtogepantDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Mean Monthly Migraine DaysTime frame: Baseline (Week 0) through Week 12
- Number of Participants Experiencing Adverse EventsTime frame: Baseline (Week 0) through Week 16
Locations
98 sites in 16 countries. Site status is shown where the registry gives one.
Rehabilitation & Neurological Services /ID# 248517
Huntsville, Alabama · Recruiting
The Center for Clinical Trials - Saraland /ID# 271604
Saraland, Alabama · Recruiting
Preferred Research Partners /ID# 249729
Little Rock, Arkansas · Recruiting
Preferred Research Partners /ID# 270406
Little Rock, Arkansas · Completed
Advanced Research Center /ID# 251381
Anaheim, California · Recruiting
Alliance for Research Alliance for Wellness /ID# 248521
Long Beach, California · Recruiting
Excell Research, Inc /ID# 247532
Oceanside, California · Completed
Lumos Clinical Research Center /ID# 249731
San Jose, California · Recruiting
Sunwise Clinical Research /ID# 248529
Walnut Creek, California · Recruiting
Advanced Neurosciences Research, LLC /ID# 247592
Fort Collins, Colorado · Completed
Northwest Florida Clinical Research Group, LLC /ID# 251382
Gulf Breeze, Florida · Completed
Advanced Research Institute of Miami /ID# 248539
Homestead, Florida · Completed
My Preferred Research LLC /ID# 249720
Miami, Florida · Recruiting
FWD Clinical Research - Spring Hill /ID# 248525
Spring Hill, Florida · Completed
Coastal Georgia Child Neurology /ID# 249733
Brunswick, Georgia · Recruiting
Deaconess Clinic - Gateway Health Center /ID# 247589
Newburgh, Indiana · Recruiting
College Park Family Care Center Overland Park /ID# 249734
Overland Park, Kansas · Completed
Michigan Headache & Neurological Institute (MHNI) /ID# 247468
Ann Arbor, Michigan · Recruiting
Proven Endpoints LLC /ID# 258066
Ridgeland, Mississippi · Recruiting
Cognitive Clinical Trials (CCT) - Papillion /ID# 248536
Papillion, Nebraska · Completed
Goryeb Childrens Hospital /ID# 249724
Morristown, New Jersey · Recruiting
Dent Neurologic Institute - Amherst /ID# 248534
Amherst, New York · Recruiting
Modern Migraine MD /ID# 258074
New York, New York · Completed
Headache Wellness Center /ID# 251018
Greensboro, North Carolina · Recruiting
Patient Priority Clinical Sites, LLC /ID# 247535
Cincinnati, Ohio · Recruiting
Cincinnati Childrens Hospital Medical Center /ID# 258070
Cincinnati, Ohio · Recruiting
CincyScience /ID# 249726
West Chester, Ohio · Completed
Lynn Institute of Oklahoma City /ID# 247600
Oklahoma City, Oklahoma · Completed
Children's Hospital of Philadelphia - Main /ID# 258071
Philadelphia, Pennsylvania · Recruiting
Le Bonheur Children's Hospital /ID# 261084
Memphis, Tennessee · Completed
Access Clinical Trials, Inc. /ID# 248532
Nashville, Tennessee · Recruiting
UT Health Austin at Dell Children's Neurology Clinic /ID# 264082
Austin, Texas · Recruiting
FutureSearch Trials of Neurology /ID# 247470
Austin, Texas · Completed
3A Research - East El Paso /ID# 248516
El Paso, Texas · Completed
Earle Research /ID# 248501
Friendswood, Texas · Recruiting
Family Psychiatry of The Woodlands /ID# 249727
The Woodlands, Texas · Completed
ClinPoint Trials /ID# 248540
Waxahachie, Texas · Recruiting
Pantheon Clinical Research /ID# 251601
Bountiful, Utah · Recruiting
Alpine Research Organization - Clinton /ID# 276497
Clinton, Utah · Recruiting
Highland Clinical Research /ID# 247590
Salt Lake City, Utah · Recruiting
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.